616 related articles for article (PubMed ID: 19221316)
1. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
Olanow CW
Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
[TBL] [Abstract][Full Text] [Related]
2. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
Schapira AH
Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314
[TBL] [Abstract][Full Text] [Related]
3. Preclinical versus clinical neuroprotection.
Grünblatt E; Schlösser R; Gerlach M; Riederer P
Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
[No Abstract] [Full Text] [Related]
4. Treatments for Parkinson disease--past achievements and current clinical needs.
Poewe W
Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
[TBL] [Abstract][Full Text] [Related]
5. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
6. Why have we failed to achieve neuroprotection in Parkinson's disease?
Olanow CW; Kieburtz K; Schapira AH
Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
[TBL] [Abstract][Full Text] [Related]
7. An update on the treatment of Parkinson's disease.
Jankovic J
Mt Sinai J Med; 2006 Jul; 73(4):682-9. PubMed ID: 16878274
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
Bhidayasiri R; Ling H
J Med Assoc Thai; 2009 Jan; 92(1):142-54. PubMed ID: 19260256
[TBL] [Abstract][Full Text] [Related]
9. When and how should treatment be started in Parkinson disease?
Lang AE
Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
[TBL] [Abstract][Full Text] [Related]
10. Treatment of early Parkinson's disease. Part 2.
Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
Eur Neurol; 2009; 61(4):206-15. PubMed ID: 19176961
[TBL] [Abstract][Full Text] [Related]
11. Early pharmacologic treatment in Parkinson's disease.
Hauser RA
Am J Manag Care; 2010 Mar; 16 Suppl Implications():S100-7. PubMed ID: 20297870
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
13. Future therapies for Parkinson's disease.
Hauser RA; Lyons KE
Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
[No Abstract] [Full Text] [Related]
14. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
Clarke CE
Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotection in Parkinson's disease: clinical trials.
Stocchi F; Olanow CW
Ann Neurol; 2003; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
[TBL] [Abstract][Full Text] [Related]
16. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
17. Drug selection and timing of initiation of treatment in early Parkinson's disease.
Schapira AH; Olanow CW
Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
[TBL] [Abstract][Full Text] [Related]
18. Treatment of early Parkinson's disease. Part 1.
Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
Eur Neurol; 2009; 61(4):193-205. PubMed ID: 19176960
[TBL] [Abstract][Full Text] [Related]
19. [Initial management and adaptation of Parkinson's disease treatment].
Gérard JM
Rev Med Brux; 2008 Sep; 29(4):229-31. PubMed ID: 18949969
[TBL] [Abstract][Full Text] [Related]
20. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
[Next] [New Search]
